Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label, Single- and Multiple-Ascending-Dose Study to Determine the Safety, Tolerability and Pharmacokinetics of Extended Release Formulations of ATN 249 in Healthy Male Participants

Next Previous
Trial Profile

An Open-Label, Single- and Multiple-Ascending-Dose Study to Determine the Safety, Tolerability and Pharmacokinetics of Extended Release Formulations of ATN 249 in Healthy Male Participants

Status: Discontinued
Phase of Trial: Phase I

Latest Information Update: 05 Jul 2019

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ATN 249 (Primary)
  • Indications Hereditary angioedema
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Attune Pharmaceuticals; LifeSci Pharmaceuticals

Most Recent Events

  • 03 Jul 2019 According to an Australian New Zealand Clinical Trials Registry, the study was stopped after completing Cohort 1 because of futility. There were no safety concerns associated with the administration of ATN 249.
  • 03 Jul 2019 Status changed to discontinued.
  • 30 Aug 2018 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top